Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease

Tino Prell; Otto W. Witte; Julian Grosskreutz

doi:10.3389/fneur.2019.00195

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease

Tino Prell^*, Otto W. Witte, Julian Grosskreutz

^*Corresponding author for this work

Friedrich Schiller University Jena

12 Citations (Scopus)

Abstract

Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical motor and non-motor symptoms. There is an urgent need for biomarkers for assessment of disease severity, complications and prognosis. In addition, biomarkers reporting the underlying pathophysiology assist in understanding the disease and developing neuroprotective therapies. Ultimately, biomarkers could be used to develop a more efficient personalized approach for clinical trials and treatment strategies. With the goal to improve quality of life in Parkinson's disease it is essential to understand and objectively monitor non-motor symptoms. This narrative review provides an overview of recent developments of biomarkers (biofluid samples and imaging) for three common neuropsychological syndromes in Parkinson's disease: dementia, fatigue, and depression.

Original language	English
Article number	195
Journal	Frontiers in Neurology
Volume	10
ISSN	1664-2295
DOIs	https://doi.org/10.3389/fneur.2019.00195
Publication status	Published - 08.03.2019
Externally published	Yes

Research Areas and Centers

Centers: Center for Neuromuscular Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fneur.2019.00195

Cite this

@article{0ac51552e9d74aec851839846f0b46a5,

title = "Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease",

abstract = "Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical motor and non-motor symptoms. There is an urgent need for biomarkers for assessment of disease severity, complications and prognosis. In addition, biomarkers reporting the underlying pathophysiology assist in understanding the disease and developing neuroprotective therapies. Ultimately, biomarkers could be used to develop a more efficient personalized approach for clinical trials and treatment strategies. With the goal to improve quality of life in Parkinson's disease it is essential to understand and objectively monitor non-motor symptoms. This narrative review provides an overview of recent developments of biomarkers (biofluid samples and imaging) for three common neuropsychological syndromes in Parkinson's disease: dementia, fatigue, and depression.",

author = "Tino Prell and Witte, {Otto W.} and Julian Grosskreutz",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2019 Prell, Witte and Grosskreutz.",

year = "2019",

month = mar,

day = "8",

doi = "10.3389/fneur.2019.00195",

language = "English",

volume = "10",

journal = "Frontiers in Neurology",

issn = "1664-2295",

}

TY - JOUR

T1 - Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease

AU - Prell, Tino

AU - Witte, Otto W.

AU - Grosskreutz, Julian

PY - 2019/3/8

Y1 - 2019/3/8

N2 - Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical motor and non-motor symptoms. There is an urgent need for biomarkers for assessment of disease severity, complications and prognosis. In addition, biomarkers reporting the underlying pathophysiology assist in understanding the disease and developing neuroprotective therapies. Ultimately, biomarkers could be used to develop a more efficient personalized approach for clinical trials and treatment strategies. With the goal to improve quality of life in Parkinson's disease it is essential to understand and objectively monitor non-motor symptoms. This narrative review provides an overview of recent developments of biomarkers (biofluid samples and imaging) for three common neuropsychological syndromes in Parkinson's disease: dementia, fatigue, and depression.

AB - Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical motor and non-motor symptoms. There is an urgent need for biomarkers for assessment of disease severity, complications and prognosis. In addition, biomarkers reporting the underlying pathophysiology assist in understanding the disease and developing neuroprotective therapies. Ultimately, biomarkers could be used to develop a more efficient personalized approach for clinical trials and treatment strategies. With the goal to improve quality of life in Parkinson's disease it is essential to understand and objectively monitor non-motor symptoms. This narrative review provides an overview of recent developments of biomarkers (biofluid samples and imaging) for three common neuropsychological syndromes in Parkinson's disease: dementia, fatigue, and depression.

UR - http://www.scopus.com/inward/record.url?scp=85075462245&partnerID=8YFLogxK

U2 - 10.3389/fneur.2019.00195

DO - 10.3389/fneur.2019.00195

M3 - Scientific review articles

AN - SCOPUS:85075462245

SN - 1664-2295

VL - 10

JO - Frontiers in Neurology

JF - Frontiers in Neurology

M1 - 195

ER -

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this